These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25096586)

  • 1. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
    Niewerth M; Minden K; Klotsche J; Horneff G
    Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
    Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
    Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
    Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of adult patients with JIA treated with the biosimilar Benepali
    Vollbach K; Tenbrock K; Wagner N; Horneff G; Klein A; Foeldvari I; Haas JP; Aries P; Gauler G; Striesow F; Hoff P; Scholz C; Tatsis S; Seipelt E; Klotsche J; Minden K
    Arthritis Res Ther; 2022 Dec; 24(1):271. PubMed ID: 36514116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis.
    Luque Ramos A; Hoffmann F; Albrecht K; Klotsche J; Zink A; Minden K
    Semin Arthritis Rheum; 2017 Oct; 47(2):269-275. PubMed ID: 28583690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients.
    Mannion ML; Xie F; Baddley J; Chen L; Curtis JR; Saag K; Zhang J; Beukelman T
    Pediatr Rheumatol Online J; 2016 Sep; 14(1):49. PubMed ID: 27596158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries.
    Kearsley-Fleet L; Klotsche J; van Straalen JW; Costello W; D'Angelo G; Giancane G; Horneff G; Klein A; Láday M; Lunt M; de Roock S; Ruperto N; Schoemaker C; Vijatov-Djuric G; Vojinovic J; Vougiouka O; Wulffraat NM; ; Hyrich KL; Minden K; Swart JF
    Rheumatology (Oxford); 2022 May; 61(6):2524-2534. PubMed ID: 34613385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.
    Drechsel P; Stüdemann K; Niewerth M; Horneff G; Fischer-Betz R; Seipelt E; Spähtling-Mestekemper S; Aries P; Zink A; Klotsche J; Minden K
    Rheumatology (Oxford); 2020 Mar; 59(3):603-612. PubMed ID: 31412128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Mannion ML; Xie F; Horton DB; Ringold S; Correll CK; Dennos A; Beukelman T;
    J Rheumatol; 2021 Aug; 48(8):1322-1329. PubMed ID: 32934124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K; Al-Maini M
    Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.